Relmada Therapeutics (RLMD) News Today $0.63 +0.03 (+4.31%) Closing price 07/3/2025 02:38 PM EasternExtended Trading$0.63 +0.00 (+0.32%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RLMD Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Relmada Therapeutics Inc News (RLMD) - Investing.comJuly 2, 2025 | investing.comRLMD Relmada Therapeutics, Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comRelmada Therapeutics' Market Cap Drops To US$22m Leaving Insiders With LossesJune 28, 2025 | uk.finance.yahoo.comRelmada Therapeutics, Inc. (RLMD) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRLMD - Relmada Therapeutics Inc Executives - MorningstarJune 24, 2025 | morningstar.comMRelmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-UrologyJune 17, 2025 | globenewswire.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Purchases $22,000.00 in StockMay 21, 2025 | insidertrades.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comRelmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comRelmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comRelmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025May 8, 2025 | globenewswire.comRelmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder CancerApril 28, 2025 | nasdaq.comRelmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025April 28, 2025 | globenewswire.comRelmada Therapeutics to hold a virtual meetingApril 27, 2025 | markets.businessinsider.comUPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025April 27, 2025 | globenewswire.comRelmada Therapeutics to Host KOL Event on Phase 2 NDV-01 DataApril 24, 2025 | globenewswire.comUPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025April 14, 2025 | globenewswire.comRelmada Therapeutics To Present NDV-01 Data at AUA2025April 14, 2025 | globenewswire.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comQ4 2024 Relmada Therapeutics Inc Earnings CallMarch 29, 2025 | uk.finance.yahoo.comRelmada Therapeutics reports Q4 EPS (62c) vs. (84c) last yearMarch 28, 2025 | markets.businessinsider.comRelmada outlines plans for NDV-01 Phase 2 results presentation and sepranolone developmentMarch 28, 2025 | msn.comRelmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comRelmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business UpdateMarch 27, 2025 | globenewswire.com4RLMD : Insights Ahead: Relmada Therapeutics's Quarterly EarningsMarch 27, 2025 | benzinga.comRelmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025March 26, 2025 | globenewswire.comRelmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.March 25, 2025 | globenewswire.comRelmada acquires new Tourette syndrome treatment assetFebruary 6, 2025 | msn.comPsychedelic: Relmada acquires neurosteroid from AsarinaFebruary 6, 2025 | markets.businessinsider.comRelmada Therapeutics acquires Sepranolone from Asarina PharmaFebruary 6, 2025 | markets.businessinsider.comRelmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma ABFebruary 6, 2025 | globenewswire.comRLMD stock touches 52-week low at $0.34 amid sharp annual declineFebruary 3, 2025 | msn.comRelmada Therapeutics faces potential Nasdaq delistingJanuary 27, 2025 | msn.comRelmada To Discontinue REL-1017 Reliance II And Relight Phase 3 Trials; Mulls SaleDecember 10, 2024 | markets.businessinsider.comRelmada Therapeutics Shifts Focus After Study DiscontinuationDecember 10, 2024 | markets.businessinsider.comRelmada seeking strategic options after failed studyDecember 10, 2024 | seekingalpha.comRelmada seeking strategic options, stock climbs 5%December 10, 2024 | msn.comRelmada discontinues late-stage trials for depression drug, explores saleDecember 9, 2024 | reuters.comRelmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017December 9, 2024 | globenewswire.comMizuho Downgrades Relmada Therapeutics (RLMD)December 6, 2024 | msn.comMizuho Securities downgrades Relmada Therapeutics (RLMD) to a HoldDecember 5, 2024 | markets.businessinsider.comLeerink Partners Downgrades Relmada Therapeutics (RLMD)December 5, 2024 | msn.comRelmada reports DMC assessment indicates Phase 3 Reliance II trial is futileDecember 5, 2024 | finance.yahoo.comRelmada Therapeutics Stock Plummets Losing 80% Value - Here's WhyDecember 4, 2024 | benzinga.comRelmada Study of Major-Depression Treatment Deemed Futile; Shares Plummet - UpdateDecember 4, 2024 | marketwatch.comRelmada Therapeutics Study of Major Depressive Disorder Treatment Assessed as FutileDecember 4, 2024 | marketwatch.comRelmada's depression drug unlikely to meet main trial goal, analysis showsDecember 4, 2024 | reuters.comRelmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical SignificanceDecember 4, 2024 | globenewswire.comVestal Point Capital LP Has $1.59 Million Stake in Relmada Therapeutics, Inc. (NASDAQ:RLMD)November 29, 2024 | marketbeat.comRelmada Therapeutics (NASDAQ:RLMD) Stock Price Down 1.4% - Here's What HappenedNovember 27, 2024 | marketbeat.com Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address RLMD Media Mentions By Week RLMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLMD News Sentiment▼0.000.58▲Average Medical News Sentiment RLMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLMD Articles This Week▼21▲RLMD Articles Average Week Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Forte Biosciences News Cellectis News Climb Bio News Cabaletta Bio News Seres Therapeutics News TScan Therapeutics News VolitionRx News Surrozen News ESSA Pharma News Pliant Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLMD) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
